In this episode of Adopt AI Talks, recorded live at the Adopt AI - Grand Palais summit in Paris, host Anca Petre of Tech Anatomy sits down with Reda Guiha, Country President France at Pfizer, to explore how AI is reshaping health from the inside of one of the world's largest pharmaceutical companies.

Reda Guiha describes a renaissance in how health is researched, delivered and followed over time. He explains why Pfizer sees itself as a builder of the ecosystem, bridging academia, startups, biotechs and the public sector, and why partnerships are, in his words, the company's lifeblood.

The conversation moves through concrete results. A 25 to 30% efficiency gain across the preclinical portfolio. Around $735 million in AI improvements in 2025, on a path toward roughly $2 billion across the value chain. AI-powered diagnostics built with BioQuantus for a rare condition often misdiagnosed as heart failure. And a clinical trial success rate lifted from around 7% to 24%.

Anca Petre and Reda Guiha also discuss the shift from reactive to proactive and predictive health, the two factors behind Pfizer's most successful use cases, and direct advice for founders who want to partner with a global pharmaceutical leader.

A practical look at what AI in health already delivers, and what it will take to scale it.

Hosted on Ausha. See ausha.co/privacy-policy for more information.